VENTYX BIOSCIENCES, INC. VTYX 深 沪
已收盘 12-19 16:00:00 美东时间
8.735
+0.995
+12.86%
华盛通- 最 高10.548
- 今 开7.78
- 成交量 144.31万股
- 最 低 7.59
- 昨 收 7.74
- 总市值 4.13亿
- 52周最高 10.548
- 市盈率 静 --
- 换手率 3.05%
- 52周最低 0.783
- 委 比 -67.84%
- 总股本 4727.03万
- 历史最高 47.2508
- 量 比 1.79
- 振 幅 38.22%
- 历史最低 0.783
- 每 手 1
- 风险率 2.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
Ventyx Biosciences executives will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025. The company, focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, will discuss its pipeline, including NLRP3 inhibitors and compounds for inflammatory bowel disease.
05-28 12:00
HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 price target.
2024-09-24 01:23
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease.
2024-09-23 23:13
Market-Moving News for September 23rd
BDTX: 54% | Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with
2024-09-23 20:10
Ventyx Biosciences Finance Chief Martin Auster Steps Down
08:17 AM EDT, 08/30/2024 (MT Newswires) -- Ventyx Biosciences (VTYX) said Friday that Martin Auster stepped down as its chief financial officer, effective the same day. The company said its senior vice president of finance, Roy Gonzales, has assumed the roles of interim principal financial and accou...
2024-08-30 20:17
Ventyx Biosciences Announces Departure Of Martin Auster As Chief Financial Officer, Effective August 30, 2024; The Company Has Initiated A Search For A CFO
Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chie...
2024-08-30 20:06
